Abstract: The invention relates to a stable disinfectant composition and the use of said composition for spraying hatching eggs prior to in ovo vaccination, for disinfecting vaccination equipment including vaccination needles, and for flushing vaccination equipment post vaccination cycles.
Abstract: The present invention is related to novel compositions comprising at least one active ingredient of the family of the triazines combined with another active ingredient and specific compounds that allow the reduction of foam formation. More particularly, the invention relates to compositions in the form of aqueous suspensions comprising a triazine, an iron complex, and one or more surfactant(s) having a particular HLB.
Type:
Grant
Filed:
October 6, 2021
Date of Patent:
February 27, 2024
Assignee:
CEVA SANTE ANIMALE
Inventors:
Anne-Claire Le Meur, Florence Guimberteau
Abstract: The present invention is related to novel compositions comprising at least one active ingredient of the family of the triazines combined with another active ingredient and specific compounds that allow the reduction of foam formation. More particularly, the invention relates to compositions in the form of aqueous suspensions comprising a triazine, an iron complex, and one or more surfactant(s) having a particular HLB.
Type:
Grant
Filed:
October 6, 2021
Date of Patent:
February 20, 2024
Assignee:
CEVA SANTE ANIMALE
Inventors:
Anne-Claire Le Meur, Florence Guimberteau
Abstract: The present invention is related to novel compositions comprising at least one active ingredient of the family of the triazines combined with another active ingredient and specific compounds that allow the reduction of foam formation. More particularly, the invention relates to compositions in the form of aqueous suspensions comprising a triazine, an iron complex, and one or more surfactant(s) having a particular HLB.
Type:
Grant
Filed:
May 13, 2022
Date of Patent:
February 20, 2024
Assignee:
CEVA SANTE ANIMALE
Inventors:
Anne-Claire Le Meur, Florence Guimberteau
Abstract: The present invention relates to a veterinary or pharmaceutical composition comprising: (i) about 1-65% w/v of a pyrethroid, or a salt thereof, (ii) a macrocyclic lactone, or a salt thereof, (iii) at least one alkalizing agent, (iv) at least one non aqueous solvent, wherein the pH of the composition is comprised between about 6.5 and 8.5, when measured by adding 25% of water to an aliquot of said composition. The invention further relates to the use of such composition for preventing and/or treating parasites infestations.
Abstract: The present invention relates to a recombinant avian herpes virus, which comprises at least two recombinant nucleotide sequences, each recombinant nucleotide sequence encoding a distinct antigenic peptide, wherein the at least two recombinant nucleotide sequences are inserted into distinct non-coding regions of the viral genome chosen among the region located between UL44 and UL45, the region located between UL45 and UL46, the region located between US10 and SORF3, and the region located between SORF3 and US2.
Abstract: The invention relates to novel veterinary compositions comprising torasemide or a pharmaceutically acceptable salt thereof and administered in domestic animals according to a predetermined dosage for symptomatic treatment of pulmonary edema associated with heart failure.
Abstract: The present invention relates to a process for preparing a solid composition comprising at least one active ingredient and at least one excipient comprising: i) mixing said at least one active ingredient and said at least one excipient in a granulator to obtain wet granules; ii) spreading wet granules on a tray and let stand for 2 to 24 hours between 15 and 25° C.; iii) compressing granules obtained after step ii) with a tablet press; and iv) collecting the solid composition. The invention further relates a solid composition obtained by such process.
Abstract: Described is a vaccine composition comprising an effective amount of at least one polypeptide selected from the group of IdeSsuis, rIdeSsuis, an analogue or a fragment thereof, or a polynucleotide encoding the same. This vaccine composition is used in the prophylactic, metaphylactic or therapeutic treatment of a Streptococcus suis infections in pigs or humans.
Type:
Application
Filed:
July 27, 2022
Publication date:
December 22, 2022
Applicant:
CEVA SANTE ANIMALE S.A.
Inventors:
Jana SEELE, Christoph BAUMS, Peter VALENTIN-WEIGAND
Abstract: The present invention describes new formulations of semiochemical compounds for mammals in wick diffusers particularly effective in controlling the diffusion of several semiochemicals having different volatilities over long periods of time and independently of the temperature and humidity conditions.
Abstract: The invention relates to a scored tablet (1) comprising a convex upper face (2), an at least partially concave lower face (3) and a side wall (4) extending between the upper and lower faces; two score grooves (5, 6) are formed in the concave lower face, said grooves being perpendicular to one another and continuous with score slits (8, 9, 10, 11) located in the side wall.
Type:
Grant
Filed:
May 22, 2018
Date of Patent:
September 13, 2022
Assignee:
CEVA SANTE ANIMALE
Inventors:
Nadège Mallo, Philippe Jolivet, Mickael Venel, Rosita Garcia
Abstract: The present invention relates to a composition of less than or equal to about 1% of pheromones useful to treat or prevent a behavioral stress problem of a non-human mammal. It also relates to a device comprising said composition and to a method for preventing and/or treating stress-related behaviors in a non-human mammal, by using said composition or device.
Abstract: The present invention relates to a new topical composition comprising niclosamide and/or oxyclozanide and to the use of said composition for the treatment or prevention of pyoderma or dermatitis in non-human mammals.
Type:
Grant
Filed:
September 14, 2018
Date of Patent:
May 17, 2022
Assignees:
CEVA SANTE ANIMALE, UNION THERAPEUTICS A/S
Abstract: The present invention is related to novel compositions comprising at least one active ingredient of the family of the triazines combined with another active ingredient and specific compounds that allow the reduction of foam formation. More particularly, the invention relates to compositions in the form of aqueous suspensions comprising a triazine, an iron complex, and one or more surfactant(s) having a particular HLB.
Type:
Grant
Filed:
December 6, 2013
Date of Patent:
May 17, 2022
Assignee:
CEVA SANTE ANIMALE
Inventors:
Anne-Claire Le Meur, Florence Guimberteau
Abstract: The present invention relates to an injectable implant comprising an effective amount of a macrocyclic lactone, or a salt thereof, and a bioresorbable polymer, and its use in preventing and/or treating parasites infestations in non human mammals, especially pets.
Abstract: The invention relates to oral pharmaceutical compositions comprising pimobendan pharmaceutically active compound. It also relates to a method for preparing the same uses thereof.
Abstract: The invention relates to the field of animal health. In particular, the invention relates to an oral solid dosage form comprising, as pharmaceutically active compounds, amlodipine. The invention relates to an oral solid dosage forms comprising an amlodipine besylate according to a particular posology for the treatment of hypertension in non-human mammal animals.
Abstract: The invention relates to novel veterinary compositions comprising an effective amount of a neonicotinoid compound and an effective amount of a N-arylpyrazole compound. The invention also relates to the use of such compositions for controlling ectoparasites in a non-human mammal.
Abstract: The present invention relates to a recombinant avian herpes virus, which comprises at least two recombinant nucleotide sequences, each recombinant nucleotide sequence encoding a distinct antigenic peptide, wherein the at least two recombinant nucleotide sequences are inserted into distinct non-coding regions of the viral genome chosen among the region located between UL44 and UL45, the region located between UL45 and UL46, the region located between US10 and SORF3, and the region located between SORF3 and US2.